Although there was an episode of acute hepatitis B virus infection in an auranofin recipient, it was thought to be unrelated to auranofin treatment on the basis of its time of onset (1 month after auranofin treatment had ended) and serological findings (conversion to HBsAg positivity accompanied by anti-HBc IgM positivity). The gene discussed is CD40LG; the disease is acute hepatitis B virus infection.